Dr. S Viswanath

About Doctor

I have been a medical oncologist in Indian Army. I have worked in various comprehensive cancer centres in Indian Army. I have been professor of medical oncology. I retired from Indian Army as Brigadier. 

 Experience

• Classified spl in Medicine and Medical Oncology
  Command Hospital(WC)- 15 May 2006 -14 May 2009.
  Assistant Professor.
• Classified spl Medicine and Medical Oncology
  Command Hospital (EC)- 20 Jun 2009 – 19 Jun 2011
  Assistant Professor.
• Senior Advisor ( Medicine & Medical Oncology)
  Command Hospital (EC)-20 Jun 2011- 15 Jun 2012
  Associate Professor.
• Senior Advisor ( Medicine & Medical Oncology)
  Army Hospital(R&R)-16 Jun 2012- 15 Jun 2016
  Associate Professor.
• Senior Advisor ( Medicine & Medical Oncology)
  Army Hospital(R&R)-16 Jun 2016- 15 Jun 2018
  Professor.
• Senior Advisor ( Medicine & Medical Oncology)
  Command Hospital (CC), Lucknow-16 Jun 2018- 04 Jan 2020.
  Professor.
• Consultant ( Medicine & Medical Oncology)
  Command Hospital (CC), Lucknow- 05 Jan 2020 – 08 Jul 2020.
  Professor.
• Commandant, Military Hospital, Chennai.
  09 Jul 2020 – 06 Apr 2021.

 Research & Publication

• Singal V K, Viswanath S, Chengappa ANM. Two cases of refractory rheumatoid arthritis treated with Rituximab; Indian Journal of Rheumatology, Vol2, Issue 3,S27:sept 2007.
• Sundaram V,Sanyal N. Clinicopathological profile of bronchogenic carcinoma in a tertiary care hospital in eastern part of India. Clinical Cancer Investig J 2014;3:220-4.
• Darling HS, Viswanath S, Rajeev V. T- lymphoblastic lymphoma in an undiagnosed rheumatoid arthritis- A rare occurrence. Indian Journal of Rheumatology,Vol. 10, Issue 1,p48-50, 2015.
• Viswanath S, Pathak A, Kapoor A, Rathore A, Kapur BN. Changing paradigm in treatment of lung cancer. J Cancer Metasta Treat 2016;2:214-9.
• Sundaram V. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman’s disease) with systemic involvement. Afr J Med Health Sci 2016;15:62-4.
• Dubey AP, Viswanath S. A case of metastatic insulinoma: Management and review of literature. OGH Reports, 2016; 5(2):79-81.
• Viswanath S, Pathak A. Management of HER2-positive breast cancer: A review. J NTR Univ Health Sci 2016;5:87-92.
• Pathak A, Viswanath S, Rathore A, Dubey AP. Paraneoplastic limbic encephalitis forgotten etiology of altered sensorium. Int J Adv Med 2016;3:771-3.
• Dubey AP*, Viswanath S, Suhag V, Pathak A, Rathore A, Kapoor A. Oral voriconazole causing severe hypokalemia, acute quadriplegia and prolonged qt interval: a rare case report, wjpmr, 2016, 2(2).
• Kapoor A, Viswanath S, Ranjan S, Kapur BN. A Clinico demographic Study of Receptor status in Carcinoma Breast. J Carcinog 2016, 15:2(7 April 2016) (ACOS Abstracts):S162.
• Rajeev V, Kapur A, Viswanath S, Kapur BN. Primary CNS Lymphoma in Immunocompetent Patient – Case Series. J Carcinog 2016, 15:2(7 April 2016) (ACOS Abstracts):S215.
• Purkayasta A, Sharma N, Viswanath S, Sunitha B. Adenoid Cystic Carcinoma of Lung: A oncological rarity treated with definitive chemoradiation.Int JCancer Ther Oncol.2016; 4(3):4315
• Purkayastha A, Pathak A, Sharma N, Viswanath S, Dutta V. Primitive neuroectodermal tumor of lungs in adults: a rare series of three cases treated with upfront chemo-radiation. Transl Lung Cancer Res 2016;5(3):350-355.
• Pathi N, Viswanath S, Pathak A, Rathore A, Prukayasta A. Receptor tyrosine kinase signalling pathways: a review. Int J Adv Med.2016 Oct 26;3(4):783-9.
• Viswanath S, Bhardwaj R, kapoor A. Clinicopathological significance of epidermal growth factor receptor and vascular endothelial growth factor expression in biliary tract malignancies. J NTR Univ Health Sci 2017;6:82-5.
• Dubey AP, Vishwanath S, Nikhil P, Rathore A, Pathak A. Microsatellite instability in stage II colorectal cancer: An Indian perspective. Indian J Cancer 2016;53:513-7.
• Dubey AP,Singh R, Pathak A, Viswanath S, Rathore A, Pathi N. Clinical profile, prognostication and treatment outcomes in non Hodgkin's lymphoma. Int J Adv Med 2017;4:1184-8.
• Singh R, Viswanath S, Maleskar D. Clinical profile and outcomes of granulocytic sarcoma among myeloid malignancies treated in a tertiary care center. Clin Cancer Investig J 2017;6:56-61.
• Carcinoma of the Unknown primary- Knowing the unknown facts. Pathak A, Gupta A, Rathore A, Vishwanath S. World J Pharm Sci2018; 6(1): 40-46.
• Dubey A P, Vishwanath S, Nikhil P, Rathore A, Pathak A, Kumar R. Microsatellite instability in stage II and III colorectal cancer: Patterns and profile. Indian J Med Paediatr Oncol [serial online] 2018 [cited 2018 Jan 29];39:36-41.
• Dubey A P, Pathi N, Rathore A, Viswanath S, Pathak A, Sud R, Rai S K. Clinicopathological profile of anaplastic lymphoma kinase-positive non small cell lung cancer: An Indian perspective. Indian J Med Paediatr Oncol [serial online] 2018 [cited 2018 Jan 29];39:32-5.
• Dubey AP, Rawat K, Pathi N, Viswanath S, Rathore A, Kapoor R, et al. Carcinoma of gall bladder: Demographic and clinicopathological profile in Indian patients. Oncol J India 2018;2:3-6.
• Purkayasta A, Sharma N, Viswanath S, Sunitha B. Adenoid Cystic Carcinoma of Lung: A oncological rarity treated with definitive chemoradiation..Int J Cancer Ther Oncol.2016; 4(3):4315
• Incidence of K-RAS mutation in metastatic colorectal carcinoma and further to find any associated correlation between K-RAS mutation and various demographic and clinical factors. A Hospital based study(#652) Altaf Ali 1 , A K Dhar 2 , Bhupender Kapur 2 , Dharmesh Soneji 2 , Amul Kapoor 2 , S Viswanath 2 E Poster 2014 WCC
• Sharma N, Purkayastha A, Vishwanath S, Jaiswal P. To compare and determine the diagnostic accuracy of [18F]- fluorodeoxyglucose positron emission tomography scan in predicting pathological response in operated carcinoma esophagus patients after initial neoadjuvant chemoradiation and neoadjuvant chemotherapy. World J Nucl Med2018;17:79-85.
• Dubey A P, Pathi N, Viswanath S, Rathore A, Pathak A, Sud R. New insights into anaplastic lymphoma kinase-positive non small cell lung cancer. Indian J Cancer 2017;54:203-8
• Rathore A, Ranjan S, Vishwanath S, Pathak A, Dubey A P, Nikhil P. BRCA 1 and 2 mutations in carcinoma breast: An Indian study. Clin Cancer Investig J 2018;7:97-103
• Darling HS, Viswanath S, Singh Randeep.Medication Related osteonecrosis of Jaw- A medical oncologist’s perspective.International Dental Journal of Student’s Research 2018;6(1):1-6
• A clinic- epidemiological, pathological and molecular study of lung cancer in Northwestern India. Darling HS, Viswanath S, Singh R, Ranjan S, Pathi N, Rathore A, Pathak A, Sud R. DOI: 10.4103/jcrt.JCRT_473_17
• Lohia, N., Prashar, M., Singh, S,Bhatnagar S, Viswanath S, Anand S, et al.Epidemiological and survival Trends in patients of Cancer of Uterine Cervix Treated with Definitive Concurrent Chemoradiotherapy: Obsevations from a North Indian Hospital Based Cancer Registry. Indian J Gynecol Oncology (2019) 17: 44
• Lohia N, Bhatnagar S, Singh S Prasher M, Subramaniam A, Viswanath S, et al. Survival trends in oral cavity cancer patients treated with surgery and adjuvant radiotherapy in a tertiary centre of Northern India. Where do we stand compared to the developed world? SRM J Res Dent Sci 2019,10 26-31.
• Prasher M, Soneji D, Viswanath S, Singh S. Cardiotoxicity with sequential use of Antharacycline and Transtuzumab in carcinoma breast patients in a North Indian tertiary care centre. J NTR Univ Health Sci 2019, 8: 83-8.
• Bisht N, Bhatnagar S, Viswanath S,Singh S, Lohia N. A comparative study of two protocols of concurrent chemotherapy with external beam radiotherapy in treatment of locally advanced cervical cancer: Cisplatin versus cisplatin plus capecitabine combination. Indian Journal of Gynecologic Oncology (2021)19:18

• Education

• MBBS - Karnataka University, India, 1988
• MD - General Medicine - Rajiv Gandhi University of Health Sciences, 2000
• DM - Medical Oncology - The Tamil Nadu Dr. M.G.R. Medical University (TNMGRMU), 2006

• Registrations

• 153389 Tamil Nadu Medical Council, 2021